Business Wire

THALES

1.7.2021 09:02:13 CEST | Business Wire | Press release

Share
High-tech Solutions From Thales Optimise the Air Passenger Experience From Home to the Airport

As airports prepare for the busy summer period, they are facing a new set of challenges; dealing with the public health crisis and complying with new regulations on freedom of movement within the Schengen Area. Thales technologies enable airport operators, airlines and border officials to enhance the travel experience and increase security at four main points around the airport.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210701005080/en/

Secure check-in
Passengers can check in remotely from any location (home, hotel, etc.) using their airline's mobile app. The identity of each individual can then be instantly verified with face recognition software, using a combination of a selfie taken by the passenger, liveness detection and a document authenticity check. The face recognition solution checks approximately 40 points on the passenger's face and issues an alert if there is any doubt about their identity.

Based on this identity verification and facial biometrics, a temporary digital token is then created for each passenger. The passenger's face then identifies them at check-in, bag drop-off, security, passport control and the boarding gate, removing the need to show a ticket and ID card at each checkpoint. The system analyses the facial features of an individual in real time, even when they are wearing a surgical mask, and matches it to the corresponding digital identity in the system. No personal data or photos are stored; an encrypted code created during check-in is the only reference the system requires.

Passengers are identified at the boarding gate in less than a second
During boarding, passengers are instantly identified by face recognition, without needing to remove their masks or show their boarding passes. In some cases, ground staff may be required to ask a passenger to show their health pass, which can be stored in a digital ID wallet on their smartphone, to prove their vaccination status, PCR test results, etc. This mobile ID wallet protects the passengers' personal data and certifies the authenticity, validity and integrity of the health data. Health passes can also be authenticated when passengers check in before arriving at the airport.

This biometric solution for boarding gates reduces boarding times by one-third. The system erases the temporary token once the aircraft has taken off.

Smart airport operations to optimise the flow of passengers
High-tech solutions from Thales also help to manage airport operations at numerous destinations. The Group provides airport operators with smart solutions and decision support tools that help them optimise and control passenger flows inside the terminal (from the entrance to the boarding and/or arrival gate). Using high-performance algorithms, these tools and solutions enable airport operators and other stakeholders to model flight arrivals and departures as well as other airport data and run simulations. Based on those simulations, they can anticipate possible travel disruptions (late or cancelled flights) and adjust resource availability on the ground to improve the passenger experience and reduce waiting times.

New border kiosks to simplify passport control for non-European nationals
Under the new requirements for member states of the Schengen Area, non-European nationals arriving in France will soon be able to use Thales's self-service border kiosks to pre-register their identity, including their biometric data (fingerprint and facial biometrics), in less than one minute.

Pre-registration offers time savings of 30% at passport control. The system software is optimised for ultra-rapid document authentication and fraud detection. Several ports of entry (airports, ports, train stations) are due to be equipped with Thales’ border kiosks between now and May 2022.

"For several decades, Thales has been helping to manage and secure sensitive infrastructure like stations, sports arenas and other major cultural venues. With its expertise in new technologies such as AI, deep learning and biometrics, boosted by the acquisition of Gemalto in 2019, Thales is in a position to provide airports and their ecosystems with new ways to increase operational efficiency, better protect the health and safety of passengers and enhance the travel experience. Thales technologies offer secure solutions that simplify the passenger experience while guaranteeing that personal data is protected and managed with complete transparency." Philippe Keryer, Executive Vice President, Strategy, Research and Technology, Thales

About Thales

Thales (Euronext Paris: HO) is a global leader in advanced technologies, investing in digital and “deep tech” innovations – connectivity, big data, artificial intelligence, cybersecurity and quantum computing – to build a confident future crucial for the development of our societies. The Group provides its customers – businesses, organisations and governments – in the defence, aeronautics, space, transport, and digital identity and security domains with solutions, services and products that help them fulfil their critical role, consideration for the individual being the driving force behind all decisions.

Thales has 81,000 employees in 68 countries. In 2020 the Group generated sales of €17 billion.

PLEASE VISIT

Thales Group
Market page

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye